Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
Sanofi said on May 14 that it has filed its anti-CD38 antibody Sarclisa (isatuximab) as an add-on to the triplet combination therapy of bortezomib, lenalidomide, and dexamethasone for the treatment of patients with untreated multiple myeloma (MM). The filing, made…
To read the full story
Related Article
BUSINESS
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
- Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- SymBio Enrolls First Patient in US for PIII BCV Trial in Adenovirus Infection
March 18, 2026
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…